The stock of Calidi Biotherapeutics Inc (CLDI) has seen a 1.18% increase in the past week, with a -37.57% drop in the past month, and a -56.46% decrease in the past quarter. The volatility ratio for the week is 7.10%, and the volatility levels for the past 30 days are at 13.42% for CLDI. The simple moving average for the past 20 days is -7.16% for CLDI’s stock, with a -43.50% simple moving average for the past 200 days.
Is It Worth Investing in Calidi Biotherapeutics Inc (AMEX: CLDI) Right Now?
The 36-month beta value for CLDI is at 0.98. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CLDI is 24.24M, and currently, shorts hold a 3.20% of that float. The average trading volume for CLDI on March 20, 2025 was 1.53M shares.
CLDI) stock’s latest price update
Calidi Biotherapeutics Inc (AMEX: CLDI) has experienced a decline in its stock price by -4.12 compared to its previous closing price of 0.84. However, the company has seen a gain of 1.18% in its stock price over the last five trading days. globenewswire.com reported 2025-03-10 that SAN DIEGO, March 10, 2025 (GLOBE NEWSWIRE) — Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced promising preclinical results for its systemic RTNova platform. The platform has successfully delivered transient gene therapy payloads to targeted tumors. Additionally, Calidi’s tumor-specific virotherapy has demonstrated efficacy in killing over 60 different tumor cell lines.
Analysts’ Opinion of CLDI
Many brokerage firms have already submitted their reports for CLDI stocks, with H.C. Wainwright repeating the rating for CLDI by listing it as a “Buy.” The predicted price for CLDI in the upcoming period, according to H.C. Wainwright is $11 based on the research report published on November 22, 2023 of the previous year 2023.
Robert W. Baird, on the other hand, stated in their research note that they expect to see CLDI reach a price target of $9. The rating they have provided for CLDI stocks is “Outperform” according to the report published on October 09th, 2023.
CLDI Trading at -17.90% from the 50-Day Moving Average
After a stumble in the market that brought CLDI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -90.30% of loss for the given period.
Volatility was left at 13.42%, however, over the last 30 days, the volatility rate increased by 7.10%, as shares sank -33.44% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -34.52% lower at present.
During the last 5 trading sessions, CLDI rose by +1.18%, which changed the moving average for the period of 200-days by -73.15% in comparison to the 20-day moving average, which settled at $0.8675. In addition, Calidi Biotherapeutics Inc saw -29.97% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CLDI starting from Camaisa Allan, who sale 10,000 shares at the price of $1.62 back on Dec 17 ’24. After this action, Camaisa Allan now owns 66,712 shares of Calidi Biotherapeutics Inc, valued at $16,200 using the latest closing price.
Stock Fundamentals for CLDI
The total capital return value is set at 5.6. Equity return is now at value -238.50, with -208.17 for asset returns.
Based on Calidi Biotherapeutics Inc (CLDI), the company’s capital structure generated -7.15 points at debt to capital in total, while cash flow to debt ratio is standing at -3.48. The debt to equity ratio resting at -0.88. The interest coverage ratio of the stock is -28.13.
Currently, EBITDA for the company is -27.58 million with net debt to EBITDA at -0.3. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.19.
Conclusion
In conclusion, Calidi Biotherapeutics Inc (CLDI) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
